BioStock: Q3 report indicates advancements for Ultimovacs

Ultimovacs is developing a universal cancer vaccine with the aim of inducing an immune response in cancer patients that is strong enough to fight off any cancer diseases. The company’s recently released Q3 report indicates steady progress for its broad pipeline. One of the highlights of the report is the confirmation of primary endpoints from the phase I trial testing UV1 in Non-small cell lung cancer (NSCLC) patients.

Read the full article at biostock.se:

https://www.biostock.se/en/q3-report-indicates-advancements-for-ultimovacs/

This is a press release from BioStock - Connecting Innovation & Capital.